US 5,182,268 A · Pharmaceutical composition comprising daunorubicin potentiated with 2,4,5-tri (4-methoxyphenyl)-4,5-dihydroimidazole

Abstract

2,4,5-Tri(4-methoxyphenyl)-4,5-dihydroimidazole, or a pharmaceutically acceptable salt thereof, is employed as a cancer drug potentiator or as an antimetastis drug.

Claims1

Dependent claims

A pharmaceutical composition useful for treatment of a cancer comprising, 2,4,5-tri (4-methoxyphenyl)-4,5-dihydroimidazole, or pharmaceutically acceptable salt thereof, in combination with daunorubicin.

Dependencies are inferred from the claim text.

Facts

Application

07/737,570Filed 26 Jul 1991 · continuation

Priority

22 Nov 1989

Granted

26 Jan 1993

Term ends

Not estimatedThe source records don’t support an estimate.

Classification4 codes

A61K 31/475
Quinolines; Isoquinolines: having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
A61K 31/415
Having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole: 1,2-Diazoles
A61K 31/70
Medicinal preparations containing organic active ingredients: carbohydrates; Sugars; Derivatives thereof
A61K
Medicines and medical preparations

Abstract

2,4,5-Tri(4-methoxyphenyl)-4,5-dihydroimidazole, or a pharmaceutically acceptable salt thereof, is employed as a cancer drug potentiator or as an antimetastis drug.

Pharmaceutical composition comprising daunorubicin potentiated with 2,4,5-tri (4-methoxyphenyl)-4,5-dihydroimidazole

Life of this patent

Abstract

Claims1

Pharmaceutical composition comprising daunorubicin potentiated with 2,4,5-tri (4-methoxyphenyl)-4,5-dihydroimidazole

Life of this patent

Abstract

Claims1